| U.S. DEPARTMENT OF COMMERCE<br>PATENT AND TRADEMARK OFFICE<br><br>INFORMATION DISCLOSURE STATEMENT BY APPLICANT<br><br>(use several sheets if necessary)<br><br>(PTO-1449 ) | ATTY. DOCKET NO.<br>19226/2071 (R-5659) | SERIAL NO.<br>09/997,936 |
|---|---|---|
| | APPLICANT<br>Balasubramanian et al. | |
| | FILING DATE<br>November 30, 2001 | GROUP ART UNIT<br>~~1646~~ 1653 |

**U.S. PATENT DOCUMENTS**

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPRO-PRIATE |
|---|---|---|---|---|---|---|---|
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |



**FOREIGN PATENT DOCUMENTS**

| | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANS-LATION IF APPRO-PRIATE |
|---|---|---|---|---|---|---|---|
| AM | 1 | WO 02/061036A2 | 08/08/02 | PCT | | | |
| | | | | | | | |

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)**

| | | | |
|---|---|---|---|
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

| EXAMINER | DATE CONSIDERED |
|---|---|
| Abdel A. Mohamed | 12/15/03 |

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | ATTY. DOCKET NO. | SERIAL NO. |
|---|---|---|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | 19226/2071 (R-5659) | 09/997,936 |
| | APPLICANT | |
| (use several sheets if necessary) | Balasubramanian et al. | |
| (PTO-1449) | FILING DATE | GROUP ART UNIT |
| | November 30, 2001 | ~~1640~~ 1653 |

OIPE JC109 NOV 15 2002 PATENT & TRADEMARK OFFICE

RECEIVED NOV 19 2002 TECH CENTER 1600/2900

**U.S. PATENT DOCUMENTS**

**FOREIGN PATENT DOCUMENTS**

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPRO-PRIATE |
|---|---|---|---|---|---|---|---|
| AM | 1 | 4,965,344 | Oct. 23, 1990 | Hermann | 530 | 351 | |
| | 2 | 5,474,892 | Dec. 12, 1995 | Jakob et al. | 435 | 4 | |
| | 3 | 5,679,582 | Oct. 21, 1997 | Bowie et al. | 436 | 518 | |
| | 4 | 5,935,810 | Aug. 10, 1999 | Friedman et al. | 435 | 69.1 | |
| | 5 | 5,981,714 | Nov. 9, 1999 | Cheng et al. | 530 | 388.2 | |
| AM | 6 | 6,348,215 B1 | Feb. 19, 2002 | Straubinger et al. | 424 | 450 | |

**FOREIGN PATENT DOCUMENTS**

| | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANS-LATION IF APPRO-PRIATE |
|---|---|---|---|---|---|---|---|
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)**

| | | | |
|---|---|---|---|
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

| EXAMINER | Abdel A. Mohamed | DATE CONSIDERED | 12/15/03 |
|---|---|---|---|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE<br>INFORMATION DISCLOSURE STATEMENT BY APPLICANT<br>(use several sheets if necessary)<br>(PTO-1449) | ATTY. DOCKET NO.<br>19226/2071 (R-5659) | SERIAL NO.<br>09/997,936 |
|---|---|---|
| | APPLICANT<br>Balasubramanian et al. | |
| | FILING DATE<br>November 30, 2001 | GROUP ART UNIT<br>~~1646~~ 1653 |



**U.S. PATENT DOCUMENTS**

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|---|---|---|---|---|---|---|---|
| AM | 1 | 5,013,556 | 05/07/1991 | Woodle et al. | 424 | 450 | |
| AM | 2 | 5,952,198 | 09/14/1999 | Chan | 435 | 69.6 | |

**FOREIGN PATENT DOCUMENTS**

| | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION IF APPROPRIATE |
|---|---|---|---|---|---|---|---|
| AM | 3 | WO 99/55306 | 11/04/1999 | WIPO | | | |
| | | | | | | | |
| | | | | | | | |

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)**

| | | | |
|---|---|---|---|
| AM | | 1 | Tavio et al., "Human Chorionic Gonadotropin in the Treatment of HIV-Related Kaposi's Sarcoma," Eur. J. Cancer, 34(10):1634-1637 (1998) |
| | | 2 | Lunardi-Iskandar et al., "Effects of a Urinary Factor From Women in Early Pregnancy on HIV-1, SIV and Associated Disease," Nature Med., 4(4):428-434 (1998) |
| | | 3 | Lee-Huang et al., "Lysozyme and RNases as Anti-HIV Components in β-core Preparations of Human Chorionic Gonadotropin," Proc. Natl. Acad. Sci. USA, 96:2678-2681 (1999) |
| | | 4 | Timasheff et al., "Preferential Binding of Solvent Components to Proteins in Mixed Water-Organic Solvent Systems," Biochem., 7(7):2501-2513 (1968) |
| | | 5 | Rariy et al., "Protein Refolding in Predominantly Organic Media Markedly Enhanced by Common Salts," Biotechnol. Bioeng., 62(6):704-710 (1999) |
| | | 6 | Rariy et al., "Correct Protein Folding in Glycerol," Proc. Natl. Acad. Sci. USA, 94:13520-13523 (1997) |
| | | 7 | Knubovets et al., "Structure, Thermostability, and Conformational Flexibility of Hen Egg-White Lysozyme Dissolved in Glycerol," Proc. Natl. Acad. Sci. USA, 96:1262-1267 (1999) |
| | | 8 | Morozova et al., "Stability of Equine Lysozyme. I. Thermal Unfolding Behaviour," Biophys. Chem., 41:185-191 (1991) |
| AM | | 9 | Ikeguchi et al., "Evidence for Identity Between the Equilibrium Unfolding Intermediate and a Transient Folding Intermediate: A Comparative Study of the Folding Reactions of α-Lactalbumin and Lysozyme," Biochem., 25:6965-6972 (1986) |

Abdel A. Mohamed — DATE CONSIDERED 12/15/03

| U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE<br>INFORMATION DISCLOSURE STATEMENT BY APPLICANT<br>(use several sheets if necessary)<br>(PTO-1449) | ATTY DOCKET NO.<br>19226/2071 (R-5659) | SERIAL NO.<br>09/997,936 |
|---|---|---|
| | APPLICANT<br>Balasubramanian et al. | |
| | FILING DATE<br>November 30, 2001 | GROUP ART UNIT<br>~~1646~~ 1653 |



**U.S. PATENT DOCUMENTS**

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|---|---|---|---|---|---|---|---|
| | | | | | | | |
| | | | | | | | |

**FOREIGN PATENT DOCUMENTS**

| | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION IF APPROPRIATE |
|---|---|---|---|---|---|---|---|
| | | | | | | | |

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

| | | | |
|---|---|---|---|
| AM | | 10 | Luo et al., "The 28-111 Disulfide Bond Constrains the α-Lactalbumin Molten Globule and Weakens Its Cooperativity of Folding," Proc. Natl. Acad. Sci. USA, 96:11283-11287 (1999) |
| | | 11 | Witzke et al., "Beta-Human Choriogonadotropin Therapy and HIV-Related Kaposi's Sarcoma," Eur. J. Med. Res., 2:155-158 (1997) |
| | | 12 | "Stability of Protein Pharmaceuticals: Part A: Chemical and Physical Pathways of Protein Degradation," in Ahern, eds., Pharmaceutical Biotechnology, Vol. 2, New York, New York:Plenum Press, pp. vii-xvii (1992) |
| AM | | 13 | "Stability of Protein Pharmaceuticals: Part B: *In Vivo* Pathways of Degradation and Strategies for Protein Stabilization," in Ahern, eds., Pharmaceutical Biotechnology, Vol. 3, New York, New York:Plenum Press, pp. vii-viii (1992) |
| | | 14 | |
| | | 15 | |
| | | 16 | |
| | | 17 | |
| | | | |
| | | | |



Abdel A. Mohamed — DATE CONSIDERED 12/15/03

| U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE<br>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT<br>(use several sheets if necessary)<br>(PTO-1449) | ATTY. DOCKET NO.<br>19226/2071 (R-5659) | SERIAL NO.<br>09/997,936 |
|---|---|---|
| | APPLICANT<br>Balasubramanjan et al. | |
| | FILING DATE<br>November 30, 2001 | GROUP ART UNIT<br>~~1646~~ 1653 |



**U.S. PATENT DOCUMENTS**

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPRO-PRIATE |
|---|---|---|---|---|---|---|---|
| | | | | | | | |
| | | | | | | | |

**FOREIGN PATENT DOCUMENTS**

| | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANS-LATION IF APPRO-PRIATE |
|---|---|---|---|---|---|---|---|
| | | | | | | | |

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)**

| | | | |
|---|---|---|---|
| AM | | 1 | Kirby et al., "Preparation of Liposomes Containing Factor VIII for Oral Treatment of Haemophilia," J. Microencapsul., 1:33-45 (1984) |
| | | 2 | Kirby et al., "Incorporation of Factor VIII Into Liposomes," Liposome Technology, Vol. II, Boca Raton, Fl:CRC Press, Inc. pp. 69-81 (1984) |
| | | 3 | Hemker et al., "Oral Treatment of Haemophilia A by Gastrointestinal Absorption of Factor VIII Entrapped in Liposomes," The Lancet, 1:70-71 (1980) |
| AM | | 4 | Röstin et al., "B-Domain Deleted Recombinant Coagulation Factor VIII Modified with Monomethoxy Polyethylene Glycol," Bioconjugate Chem., 11:387-396 (2000) |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

| EXAMINER | Abdel A. Mohamed | DATE CONSIDERED | 12/15/03 |
|---|---|---|---|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE<br>INFORMATION DISCLOSURE STATEMENT BY APPLICANT<br>(use several sheets if necessary)<br>(PTO-1449) | ATTY. DOCKET NO.<br>19226/2071 (R-5659) | SERIAL NO.<br>09/997,936 |
|---|---|---|
| | APPLICANT<br>Balasubramanian et al. | |
| | FILING DATE<br>November 30, 2001 | GROUP ART UNIT<br>~~1646~~ 1653 |



**U.S. PATENT DOCUMENTS**

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPRO-PRIATE |
|---|---|---|---|---|---|---|---|
| | | | | | | | |
| | | | | | | | |

**FOREIGN PATENT DOCUMENTS**

| | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANS-LATION IF APPRO-PRIATE |
|---|---|---|---|---|---|---|---|
| | | | | | | | |

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)**

| | | | |
|---|---|---|---|
| AM | | 1 | Larner, "The Molecular Pathology of Haemophilia," Quarterly J. Med., 63(242):473-491 (1987) |
| | | 2 | Toole et al., "Molecular Cloning of a cDNA Encoding Human Antihaemophilic Factor," Nature, 312:342-347 (1984) |
| | | 3 | Wood et al., "Expression of Active Human Factor VIII From Recombinant DNA Clones," Nature, 312:330-336 (1984) |
| | | 4 | Fay, "Factor VIII Structure and Function," Thrombosis and Haemostasis, 70(1):63-67 (1993) |
| | | 5 | Foster et al., "Factor VIII Structure and Function," Blood Reviews, 3:180-191 (1989) |
| | | 6 | Yoshimoto et al., "Oxidative Refolding of Denatured/Reduced Lysozyme Utilizing the Chaperone-Like Function of Liposomes and Immobilized Liposome Chromatography," Biotechnol. Prog., 15:480-487 (1999) |
| | | 7 | Balasubramanian et al., "Liposomes as Formulation Excipients for Protein Pharmaceuticals: A Model Protein Study," Pharm. Res., 17(3):344-350 (2000) |
| | | 8 | Kanaoka et al., "Stabilization of Aerosolized IFN-γ by Liposomes," Int. J. Pharmaceutics, 188:165-172 (1999) |
| | | 9 | Woodle, "Surface-Modified Liposomes: Assessment and Characterization for Increased Stability and Prolonged Blood Circulation," Chem. Phys. Lipids, 64:249-262 (1993) |
| AM | | 10 | Gilbert et al., "Specificity of Phosphatidylserine-Containing Membrane Binding Sites for Factor VIII," J. Biol. Chem., 267(22):15861-15868 (1992) |

| EXAMINER | Abdel A-Mohamed | DATE CONSIDERED | 12/15/03 |
|---|---|---|---|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE<br>INFORMATION DISCLOSURE STATEMENT BY APPLICANT<br>(use several sheets if necessary)<br>(PTO-1449) | ATTY. DOCKET NO.<br>19226/2071 (R-5659) | SERIAL NO.<br>09/997,936 |
|---|---|---|
| | APPLICANT<br>Balasubramanian et al. | |
| | FILING DATE<br>November 30, 2001 | GROUP ART UNIT<br>~~1646~~ 1653 |



**U.S. PATENT DOCUMENTS**

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPRO-PRIATE |
|---|---|---|---|---|---|---|---|
| | | | | | | | |
| | | | | | | | |

**FOREIGN PATENT DOCUMENTS**

| | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANS-LATION IF APPRO-PRIATE |
|---|---|---|---|---|---|---|---|
| | | | | | | | |

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)**

| | | | |
|---|---|---|---|
| AM | | 11 | Gilbert et al., "Specific Membrane Binding of Factor VIII is Mediated by O-Phospho-L-Serine, A Moiety of Phosphatidylserine," Biochem., 32:9577-9587 (1993) |
| | | 12 | Gilbert et al., "Binding of Human Factor VIII to Phospholipid Vesicles," J. Biol. Chem., 265(2):815-822 (1990) |
| | | 13 | Hilbich et al., "Aggregation and Secondary Structure of Synthetic Amyloid βA4 Peptides of Alzheimer's Disease," J. Mol. Biol., 218:149-163 (1991) |
| | | 14 | Hammarström et al., "Structural Mapping of an Aggregation Nucleation Site in a Molten Globule Intermediate," J. Biol. Chem., 274(46):32897-32903 (1999) |
| | | 15 | Tsai et al., "Formulation Design of Acidic Fibroblast Growth Factor," Pharmaceutical Res., 10(5):649-659 (1993) |
| | | 16 | Carpenter et al., "Rational Design of Stable Lyophilized Protein Formulations: Some Practical Advice," Pharmaceutical Res., 14(8):969-975 (1997) |
| | | 17 | Foster et al., "Synthetic Factor VIII Peptides With Amino Acid Sequences Contained Within the C2 Domain of Factor VIII Inhibit Factor VIII Binding to Phosphatidylserine," Blood, 75(10):1999-2004 (1990) |
| | | 18 | Kalafatis et al., "Factor Va-Membrane Interaction is Mediated by Two Regioins Located on the Light Chain of the Cofactor," Biochem., 33:486-493 (1994) |
| ✓ | | 19 | Lecompte, et al. "Electrostatic and Hydrophobic Interactions Are Involved in Factor Va Binding to Membranes Containing Acidic Phospholipids," J. Biol. Chem., 269(3):1905-1910 (1994) |
| AM | | 20 | Saenko et al., "A Mechanism for Inhibition of Factor VIII Binding to Phospholipid by von Willebrand Factor," J. Biol. Chem., 270(23):13826-13833 (1995) |

| EXAMINER | Abdel A. Mohamed | DATE CONSIDERED | 12/15/03 |
|---|---|---|---|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE<br>INFORMATION DISCLOSURE STATEMENT BY APPLICANT<br>(use several sheets if necessary)<br>(PTO-1449) | ATTY. DOCKET NO.<br>19226/2071 (R-5659) | SERIAL NO.<br>09/997,936 |
|---|---|---|
| | APPLICANT<br>Balasubramanian et al. | |
| | FILING DATE<br>November 30, 2001 | GROUP ART UNIT<br>1646 1653 |





**U.S. PATENT DOCUMENTS**

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPRO-PRIATE |
|---|---|---|---|---|---|---|---|
| | | | | | | | |
| | | | | | | | |

**FOREIGN PATENT DOCUMENTS**

| | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANS-LATION IF APPRO-PRIATE |
|---|---|---|---|---|---|---|---|
| | | | | | | | |

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

| | | | |
|---|---|---|---|
| AM | | 21 | Scandella et al., "In Hemophilia A and Autoantibody Inhibitor Patients: The Factor VIII A2 Domain and Light Chain Are Most Immunogenic," Thrombosis Res., 101:377-385 (2001) |
| | | 22 | Woodle et al., "Versatility in Lipid Compositions Showing Prolonged Circulation with Sterically Stabilized Liposomes," Biochimica et Biophysica Acta., 1105:193-200 (1992) |
| | | 23 | Klibanov et al., "Amphipathic Polyethyleneglycols Effectively Prolong the Circulation Time of Liposomes," FEBS Letters, 268:235-237 (1990) |
| | | 24 | Papahadjopoulos et al., "Sterically Stabilized Liposomes: Improvements in Pharmacokinetics and Antitumor Therapeutic Efficacy," Proc. Natl. Acad. Sci. USA, 88:11460-11464 (1991) |
| | | 25 | Lasic et al., "Sterically Stabilized Liposomes: A Hypothesis on the Molecular Origin of the Extended Circulation Times," Biochimica et Biophysica Acta, 1070:187-192 (1991) |
| | | 26 | Pan et al., "Proposed Structure of the A Domains of Factor VIII by Homology Modelling," Nature Structural Biol., 2(9):740-744 (1995) |
| | | 27 | Purohit et al., "Mutants of Human Choriogonadotropin Lacking *N*-Glycosyl Chains in the α-Subunit. 1. Mechanism for the Differential Action of the N-Linked Carbohydrates," Biochem., 36:12355-12363 (1997) |
| | | 28 | Aloj et al., "Interaction of 1, 8-ANS Wwith Human Luteinizing Hormones: A Probe for Subunit Interactions of hCG and hLH," Archives of Biochem. and Biophysics, 165:478-479 (1973) |
| | | 29 | Balasubramanian et al., "Interferon-γ-Inhibitory Oligodeoxynucleotides Alter the Conformation of Interferon-γ," Molecular Pharmacol., 53:926-932 (1998) |
| AM | | 30 | Lakowicz, Principles of Fluorescence Spectroscopy, Second Edition, New York, New York:Plenum Publishers, pp. 51-54 (1999) |

| EXAMINER | Abdel A. Mohamed | DATE CONSIDERED | 12/15/03 |
|---|---|---|---|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE<br>INFORMATION DISCLOSURE STATEMENT BY APPLICANT<br>(use several sheets if necessary)<br>(PTO-1449 ) | ATTY. DOCKET NO.<br>19226/2071 (R-5659) | SERIAL NO.<br>09/997,936 |
|---|---|---|
| | APPLICANT<br>Balasubramanian et al. | |
| | FILING DATE<br>November 30, 2001 | GROUP ART UNIT<br>~~1646~~ 1653 |





**U.S. PATENT DOCUMENTS**

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPRO-PRIATE |
|---|---|---|---|---|---|---|---|
| | | | | | | | |
| | | | | | | | |

**FOREIGN PATENT DOCUMENTS**

| | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANS-LATION IF APPRO-PRIATE |
|---|---|---|---|---|---|---|---|
| | | | | | | | |

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)**

| | | | |
|---|---|---|---|
| AM | | 31 | Ptitsyn et al., "Evidence For a Molten Globule State as a General Intermediate in Protein Folding," FEBS. Letters, 262(1):20-24 (1990) |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

| EXAMINER | Abdel A. Mohamed | DATE CONSIDERED | 12/15/03 |
|---|---|---|---|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.